Is Mounjaro a GLP-1 medicine — and why does the distinction matter?

What NICE and the NHS actually say about how tirzepatide works

When NICE published its appraisal of tirzepatide (TA1026, December 2024, updated September 2025), the committee repeatedly noted the dual-agonist mechanism as a factor when weighing tirzepatide against semaglutide. GLP-1 receptor agonists (medicines like semaglutide) mimic one post-meal hormone signal. Tirzepatide mimics two. The GIP receptor had long been considered a secondary target, but combining GIP and GLP-1 activation appears to produce appetite suppression and metabolic effects that are additive rather than simply overlapping.

The SURMOUNT-1 trial, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and no diabetes across three tirzepatide doses and placebo. At 72 weeks, the 15 mg arm produced average body-weight reductions of around 20–21%. That figure sits above what semaglutide 2.4 mg achieved in equivalent timeframes, and the SURMOUNT-5 head-to-head trial (NEJM, 2025) confirmed tirzepatide's greater average weight reduction in a direct comparison. The dual mechanism is the leading explanation researchers give for that gap.

Practically, both receptor pathways slow the rate at which food leaves the stomach and send satiety signals to the brain. The GIP component also influences how the body handles fat storage. Neither effect operates in isolation, the two pathways interact in ways that are still being studied, which is partly why Mounjaro carries the Black Triangle designation. You can read more about the pharmacology of tirzepatide if you want the deeper science.

GLP-1 alone versus GIP-plus-GLP-1: what this means for results and side effects

Single-receptor GLP-1 medicines target one pathway. Adding the GIP receptor changes the profile in two ways that matter to patients.

First, the weight-loss data differs. Semaglutide 2.4 mg (Wegovy) produced around 15% average weight reduction in the STEP 1 trial. Tirzepatide's figures, as described above, ran higher, a difference the NICE committee acknowledged when reviewing indirect comparisons. The newer 7.2 mg semaglutide dose narrows that gap, but the head-to-head data still favours tirzepatide.

Second, the side-effect profile is broadly similar in character but not identical. Both drug classes produce mostly gastrointestinal symptoms (nausea, loose stools, constipation, indigestion) that tend to cluster around dose increases and ease as the body adjusts. The SURMOUNT-1 trial showed this GI pattern with tirzepatide; the NHS medicines page for tirzepatide lists the same categories. The mechanism differs at receptor level, but the gut-settling advice is the same: eat smaller portions, avoid high-fat food around the time of the injection, and stay hydrated. If you are specifically researching how the mechanism translates into your options, the explainer on what Mounjaro is covers the full licensed indication in plain English.

One quick check worth doing right now: look at the product packaging or the Patient Information Leaflet and confirm the medicine is manufactured by Eli Lilly. The KwikPen's lot number and Lilly's name appear on the outer carton. Genuine pens sourced through the licensed UK supply chain carry both; fakes frequently do not.

Does the GLP-1 versus dual-agonist distinction change who can use Mounjaro?

In terms of licensing, both Mounjaro and Wegovy are indicated for weight management in adults with a BMI of 30 or above, or 27 or above alongside a weight-related condition such as hypertension, dyslipidaemia, obstructive sleep apnoea or type 2 diabetes. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance. If you are wondering whether Mounjaro qualifies as a GLP-1 medicine and what that classification means in practice, the dual mechanism does not itself alter the eligibility criteria, as both medicines occupy the same licensed space for private prescription.

Where the distinction becomes clinically relevant is in the prescriber's assessment of which medicine is more appropriate for an individual patient. Someone already established on a GLP-1 medicine who has not reached their target may be considered for tirzepatide; someone with certain conditions such as hidradenitis suppurativa, which researchers are actively investigating in relation to tirzepatide, may have additional factors worth discussing with a prescriber. A prescriber makes that call, not a checklist. For a fuller look at private prescription routes, our guide to accessing Mounjaro through a regulated UK pharmacy covers what the process involves.

On the NHS, NICE's TA1026 recommends tirzepatide for adults with a BMI of 35 or above plus at least one weight-related comorbidity, within a phased rollout through primary care. Semaglutide under TA875 requires use within a specialist weight management service for a maximum of two years. The mechanisms differ; the access criteria reflect those separate appraisals rather than the receptor pharmacology itself. A broader overview of treatment options sits on our weight-loss treatment page.

Why the 'GLP-1 drug' label sticks, and when it matters to correct it

Most people searching this question have read somewhere that Mounjaro is a GLP-1 drug and want to know if that is accurate. It is partly accurate. The GLP-1 receptor is one of tirzepatide's two targets, so the label is not wrong, it is incomplete. The shorthand persists because GLP-1 medicines became widely known first (semaglutide, liraglutide) and the category name stuck. Calling tirzepatide a GLP-1 drug is a bit like calling a four-wheel-drive car a two-wheel-drive car because it also has a front axle.

The distinction matters most when you are comparing options, reading trial data, or understanding why your prescriber might suggest one medicine over another. It matters less day-to-day once you are on treatment. If you would like to explore how Mounjaro's dual-agonist mechanism sits within the broader context of its licensed use and clinical evidence, that page takes the receptor science a step further.

Mounjaro is a prescription-only medicine. If you are considering it, our clinical team reviews consultations the same day, a real prescriber, reading your answers, making a clinical judgement. Speak to our prescribers through a free consultation if you would like to explore whether tirzepatide is suitable for you.